BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...

In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...

BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy (ATTR-CM) ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

Scotiabank has recently initiated BridgeBio Pharma Inc (BBIO) stock to Sector Outperform rating, as announced on October 16, 2024, according to Finviz. Earlier, on October 3, 2024, Oppenheimer had ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...

Invesco Health Care Fund underperformed its benchmark. Despite earlier signs of improving trends, our health care outlook is ...

Trump Vows to Hit Mexico, Canada and China With Tariff on Day 1 President-elect Trump promised a 25 percent tariff on Canada and Mexico, and an additional 10 percent on China, blaming the flow of ...

Company has Deloitte Haskins & Sells LLP as its auditors. As on 30-06-2024, the company has a total of 16.94 Crore shares outstanding.GSK Pharma Share Price Today is Rs. 2397.45 as on 25 Nov, 2024, 12 ...